Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Antipsychotic polypharmacy: a Japanese survey of prescribers' attitudes and rationales.

Kishimoto T, Watanabe K, Uchida H, Mimura M, Kane JM, Correll CU.

Psychiatry Res. 2013 Oct 30;209(3):406-11. doi: 10.1016/j.psychres.2013.03.014. Epub 2013 Apr 18.

2.

Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior.

Correll CU, Shaikh L, Gallego JA, Nachbar J, Olshanskiy V, Kishimoto T, Kane JM.

Schizophr Res. 2011 Sep;131(1-3):58-62. doi: 10.1016/j.schres.2011.02.016. Epub 2011 Mar 21.

3.

Attitudes towards and rationale for antipsychotic polypharmacy among psychiatrists in Nigeria: Characteristics associated with high reported antipsychotic polypharmacy.

James BO, Omoaregba JO, Raji SO, Imishue OE, Okonoda KM, Nyamali YI, Famuyiwa PA, Correll CU.

Psychiatry Res. 2017 Feb;248:134-139. doi: 10.1016/j.psychres.2016.12.032. Epub 2016 Dec 27.

PMID:
28063386
4.

Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study.

Sneider B, Pristed SG, Correll CU, Nielsen J.

Eur Neuropsychopharmacol. 2015 Oct;25(10):1669-76. doi: 10.1016/j.euroneuro.2015.04.027. Epub 2015 May 7.

PMID:
26256007
5.

Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: findings of the third national survey on use of psychotropic medications in China.

Li Q, Xiang YT, Su YA, Shu L, Yu X, Chiu HF, Correll CU, Ungvari GS, Lai KY, Ma C, Wang GH, Bai PS, Li T, Sun LZ, Shi JG, Chen XS, Mei QY, Li KQ, Si TM.

Aust N Z J Psychiatry. 2015 Feb;49(2):129-36. doi: 10.1177/0004867414536931. Epub 2014 Jun 12.

PMID:
24923760
6.

Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Correll CU, Gallego JA.

Psychiatr Clin North Am. 2012 Sep;35(3):661-81. doi: 10.1016/j.psc.2012.06.007. Epub 2012 Jul 24. Review.

7.

Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009).

Xiang YT, Wang CY, Si TM, Lee EH, He YL, Ungvari GS, Chiu HF, Yang SY, Chong MY, Tan CH, Kua EH, Fujii S, Sim K, Yong KH, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Shinfuku N.

Pharmacopsychiatry. 2012 Jan;45(1):7-12. doi: 10.1055/s-0031-1286345. Epub 2011 Oct 11.

PMID:
21989602
8.

Variation in long-term antipsychotic polypharmacy and high-dose prescribing across physicians and hospitals.

Latimer EA, Naidu A, Moodie EE, Clark RE, Malla AK, Tamblyn R, Wynant W.

Psychiatr Serv. 2014 Oct;65(10):1210-7. doi: 10.1176/appi.ps.201300217.

PMID:
24981557
9.

Antipsychotic polypharmacy among elderly patients with schizophrenia and dementia during hospitalization at a Taiwanese psychiatric hospital.

Wu YH, Lai CY, Chang YS.

Psychogeriatrics. 2015 Mar;15(1):7-13. doi: 10.1111/psyg.12067. Epub 2014 Dec 17.

10.

Excessive dosing and polypharmacy of antipsychotics caused by pro re nata in agitated patients with schizophrenia.

Fujita J, Nishida A, Sakata M, Noda T, Ito H.

Psychiatry Clin Neurosci. 2013 Jul;67(5):345-51. doi: 10.1111/pcn.12056. Epub 2013 May 28.

11.

Prescribing of Clozapine and Antipsychotic Polypharmacy for Schizophrenia in a Large Medicaid Program.

Tang Y, Horvitz-Lennon M, Gellad WF, Lave JR, Chang CH, Normand SL, Donohue JM.

Psychiatr Serv. 2017 Jun 1;68(6):579-586. doi: 10.1176/appi.ps.201600041. Epub 2017 Feb 15.

PMID:
28196460
12.

Prevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: a nationwide retrospective cohort study.

Okumura Y, Ito H, Kobayashi M, Mayahara K, Matsumoto Y, Hirakawa J.

Schizophr Res. 2010 Jun;119(1-3):145-52. doi: 10.1016/j.schres.2010.02.1061. Epub 2010 Mar 20.

PMID:
20304611
13.

Prevalence and nature of antipsychotic polypharmacy among inpatients with schizophrenia spectrum disorders at an Australian mental health service.

John AP, Gee T, Alexander S, Ramankutty P, Dragovic M.

Australas Psychiatry. 2014 Dec;22(6):546-50. doi: 10.1177/1039856214546672. Epub 2014 Aug 21.

PMID:
25147317
14.

Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment.

Toteja N, Gallego JA, Saito E, Gerhard T, Winterstein A, Olfson M, Correll CU.

Int J Neuropsychopharmacol. 2014 Jul;17(7):1095-105. doi: 10.1017/S1461145712001320. Epub 2013 May 14. Review.

15.

Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process.

Kadra G, Stewart R, Shetty H, Jackson RG, Greenwood MA, Roberts A, Chang CK, MacCabe JH, Hayes RD.

BMC Psychiatry. 2015 Jul 22;15:166. doi: 10.1186/s12888-015-0557-z.

16.

Best practices: An initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital.

Patrick V, Schleifer SJ, Nurenberg JR, Gill KJ.

Psychiatr Serv. 2006 Jan;57(1):21-3.

PMID:
16399958
17.

Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription.

Ito H, Koyama A, Higuchi T.

Br J Psychiatry. 2005 Sep;187:243-7.

PMID:
16135861
18.

Development and delivery of a quality improvement program to reduce antipsychotic polytherapy.

Gören JL, Beck SE, Mills BJ, Shtasel DL, Dufresne RL.

J Manag Care Pharm. 2010 Jul-Aug;16(6):393-401.

19.

Common use of antipsychotic polypharmacy in older Asian patients with schizophrenia (2001-2009).

Xiang YT, Dickerson F, Kreyenbuhl J, Ungvari GS, Wang CY, Si TM, Lee EH, He YL, Chiu HF, Yang SY, Chong MY, Tan CH, Kua EH, Fujii S, Sim K, Yong MK, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Shinfuku N.

J Clin Psychopharmacol. 2012 Dec;32(6):809-13. doi: 10.1097/JCP.0b013e3182726623.

PMID:
23131883
20.

Antipsychotic polypharmacy in schizophrenia: benefits and risks.

Barnes TR, Paton C.

CNS Drugs. 2011 May;25(5):383-99. doi: 10.2165/11587810-000000000-00000. Review.

PMID:
21476610

Supplemental Content

Support Center